Le baricitinib renforce les effets modificateurs de la maladie en dissociant le lien entre l'activité de la maladie et la progression de la structure articulaire chez les patients atteints de polyarthrite rhumatoïde
Ann Rheum Dis. 2022. Epub ahead of print doi: 10.1136/annrheumdis-2021-221323
Baricitinib reduces structural damage progression versus placebo with background MTX and/or MTX, even in patients with moderate or high disease activity.In patients with RA, TNFi, IL-6i and rituximab have been shown to uncouple the link between disease activity and radiographic progression such that patients are protected from structural damage progression even if remission/low disease activity is not achieved.As such, Lopez-Romero, et al. aimed to evaluate if baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and structural damage progression in patients with RA.
